Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2009

View Archived Issues

Lilly and Incyte sign license and collaboration agreement for INCB-28050

Teva and OncoGenex sign license and collaboration agreement for OGX-011

Ipsen discloses preliminary data from phase I trial of BN-83495 in breast cancer

Ligand completes acquisition of Neurogen

pSivida reports 24-month results from phase III FAME study of Iluvien for DME

Bryan Oncor reports results of phase I trial of radiolabeled P-2045 in advanced lung cancer

Thallion to close phase II trial of TLN-4601 for glioblastoma multiforme

Applied NeuroSolutions and Lilly agree to increase the scope of their AD collaboration

FDA clears Dilon Diagnostics' GammaLoc for molecular imaging biopsy guidance

Solvay submits NDA in Japan for pancrelipase for pancreatic exocrine insufficiency

FDA approves Sanofi Pasteur's High-Dose Fluzone vaccine for people aged 65 years and older

FDA issues complete response letter for Pfizer's NDA for Lyrica in GAD

Janssen discovers novel antibacterial agents

Enanta Pharmaceuticals discloses NS3 protease inhibitors for HCV infection

GSK presents novel compounds for the treatment of anemia

Novel MAPKAP5 inhibitors in development at Galapagos for the treatment of RA

Merck & Co. developing novel BACE1 inhibitors for neurologic conditions

Gilead discovers novel NS5B inhibitors for the treatment HCV infections

Allergan claims prostanoid EP2 receptor activators for glaucoma therapy

Kappa-opioid receptor antagonists claimed by Janssen for treatment of addiction

Ferrous sulfate may improve restless legs syndrome symptoms

Interim study results suggest AE-37 vaccine may reduce breast cancer recurrence

BSI-201 added to gemcitabine/carboplatin improves survival in metastatic TNBC

Intercell initiates pediatric phase III study of Japanese encephalitis vaccine

FDA accepts for review Questcor's sNDA for H.P. Acthar Gel for infantile spasms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...